Loading stock data…
Genelux Corporation (GNLX)
$2.90+0.03 (+1.05%)
After Hours$2.90+0.00 (+0.00%)· Last close Jun 29
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Genelux Corporation in the Healthcare sector is trading at $2.90 with a market capitalization of $133M. Wall Street consensus targets $17.50 (6 analysts), implying a +503.4% move over the next 12 months. The stock is currently near its 52-week low of $2.29, remaining 21.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +503.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $8,000 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$9.17M↑ | -$9.41M↓ | -$8.19M↓ | -$7.79M↑ | -$7.82M |
| Net Income | -$8.93M↑ | -$9.25M↓ | -$7.95M↓ | -$7.46M↑ | -$7.49M |
Peer Comparison
JNJUNHPFE
Fundamentals
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimul...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$132.73M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-146.51%
Volume
Today's trading volume
200,207
Recent News
Institutions along with retail investors who hold considerable shares inGenelux Corporation (NASDAQ:GNLX) come under pressure; lose 16% of holdings value
Key Insights The considerable ownership by retail investors in Genelux indicates that they collectively have a greater...
Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
3 Promising Penny Stocks With Market Caps Under $200M
Major indexes in the United States are experiencing mixed performances, with tech stocks rallying and bank stocks sliding following recent inflation data. In this context, penny stocks remain a compelling area of interest for investors looking for potential growth opportunities. Although the term 'penny stocks' may seem outdated, these smaller or newer companies can offer significant value when backed by strong financials. Let's explore several such penny stocks that stand out for their...